McCombs Institute for the Early Detection and Treatment of Cancer

Medicine & Life Sciences

1. Neoplasms 100%
2. Ewing's Sarcoma 86%
3. Desmoplastic Small Round Cell Tumor 78%
4. Adenocarcinoma 71%
5. Proteomics 63%
6. Proteins 63%
7. Extracellular Vesicles 55%
8. Neoplasm Metastasis 50%
9. Adenocarcinoma of Lung 47%
10. Pancreatic Neoplasms 46%
11. Biomarkers 45%
12. Polyamines 39%
13. Lung Neoplasms 39%
14. Tumor Microenvironment 31%
15. Sarcoma 31%
16. Phosphatidylinositol 3-Kinases 31%
17. Ovarian Neoplasms 30%
18. Therapeutics 30%
19. Osteosarcoma 30%
20. Cell Line 28%
21. kynureninase 28%
22. Small Cell Sarcoma 28%
23. Prostatic Neoplasms 27%
24. Autoantibodies 26%
25. Breast Neoplasms 26%
26. Drug Resistance 25%
27. Cell Dedifferentiation 23%
28. Metabolomics 23%
29. Early Detection of Cancer 22%
30. Survival 22%
31. Multiple Endocrine Neoplasia Type 1 22%
32. Neoplasm Antigens 22%
33. Blood Proteins 21%
34. Phenotype 21%
35. Triple Negative Breast Neoplasms 21%
36. Perforator Flap 21%
37. Carboxylesterase 21%
38. Hereditary Nonpolyposis Colorectal Neoplasms 20%
39. Caveolin 1 20%
40. Proteome 20%
41. Mass Spectrometry 19%
42. Bone Neoplasms 19%
43. Sphingolipids 19%
44. Indocyanine Green 18%
45. Heterografts 18%
46. Peritoneal Neoplasms 18%
47. B-Lymphocytes 17%
48. Antigens 17%
49. Androgen Receptors 17%
50. Neuroendocrine Tumors 17%
51. Stomach 17%
52. Small Cell Lung Carcinoma 17%
53. Optical Imaging 17%
54. Carcinogenesis 17%
55. Growth 17%
56. Long Noncoding RNA 17%
57. Perfusion 16%
58. YK 4-279 16%
59. Immunoglobulins 16%
60. Exosomes 16%
61. Up-Regulation 16%
62. Kynurenine 16%
63. TIC10 compound 15%
64. IGF Type 1 Receptor 15%
65. Autoimmunity 15%
66. Drug Therapy 15%
67. Epithelial-Mesenchymal Transition 14%
68. Colorectal Neoplasms 14%
69. Growth Factor Receptors 14%
70. In Vitro Techniques 14%
71. Serum 14%
72. Immunosuppression 14%
73. Non-Small Cell Lung Carcinoma 14%
74. Cold Temperature 14%
75. Area Under Curve 13%
76. Small Interfering RNA 13%
77. Antineoplastic Agents 13%
78. Genes 13%
79. Risk Assessment 13%
80. Proteogenomics 13%
81. Peptides 13%
82. Oncogenes 13%
83. Immunity 12%
84. T-Lymphocytes 12%
85. venetoclax 12%
86. RNA Sequence Analysis 12%
87. Cell Proliferation 12%
88. Mesenchymal Stem Cells 12%
89. Pharmaceutical Preparations 11%
90. dalotuzumab 11%
91. Disease Progression 11%
92. pazopanib 11%
93. PCI 32765 11%
94. Neuropilin-1 11%
95. Thyroid Nuclear Factor 1 11%
96. Mutation 11%
97. Transcriptome 11%
98. Extracellular Matrix 11%
99. Proto-Oncogene Proteins c-myc 11%